Edward Gane

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

H. Harputluoglu, S. Yoon, H. Marusawa, 2023, The Lancet.

Trial Results : Telbivudine Is Superior to Lamivudine in atients With Chronic Hepatitis B UN –

M. Manns, Y. Liaw, Ching-lung Lai, 2022 .

PHOCUS: A Phase 3, Randomized, Open-Label Study of Sequential Treatment with Pexa-Vec (JX-594) and Sorafenib in Patients with Advanced Hepatocellular Carcinoma

M. Borad, G. Abou-Alfa, C. Breitbach, 2023, Liver Cancer.